This page shows the latest NTDT news and features for those working in and with pharma, biotech and healthcare.
Novartis' Exjade (deferasirox) has received European approval as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, a group of genetic disorders characterised by red blood cell problems and anaemia. ... This approval is a critical
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...